Background. Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks postpartum risks selection of resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs). We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations.
), the median HIV load was 3.45 log 10 copies/mL (IQR, 2.79-4.00 log 10 copies/mL), and the median duration of zidovudine prophylaxis was 10.4 weeks (IQR, 9.1-11.4 weeks). Using consensus sequencing, major NNRTI resistance mutations were detected after delivery in 0% of PHPT-4 subjects and 10.4% of PHPT-2 controls. The oligonucleotide ligation assay detected resistance in 1.8% of PHPT-4 subjects and 18.9% of controls. Major NNRTI resistance mutations were detected by either method in 1.8% of PHPT-4 subjects and 20.7% of controls ( ). P ! .001 Conclusions. A 1-month postpartum course of zidovudine plus didanosine prevented the selection of the vast majority of NNRTI resistance mutations.
Single-dose nevirapine given to human immunodeficiency virus (HIV)-infected women at onset of labor and newborns, in addition to antenatal zidovudine or if HIV infection is diagnosed late during labor, single-dose nevirapine remains essential to diminish intrapartum transmission.
Unfortunately, HIV resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) can be selected within weeks after single-dose nevirapine administration [6] [7] [8] [9] [10] and have been associated with a decrease in the virologic efficacy of subsequent NNRTI-based HAART regimens when women initiate therapy for their own health [8, 11, 12] . Although factors associated with selection of these mutations are not fully understood, it is postulated to occur as long as nevirapine persists in the plasma [13] in the presence of viral replication. We hypothesized that a 1-month postpartum course of zidovudine plus didanosine following exposure to single-dose nevirapine would prevent the selection of resistance mutations by suppressing viral replication. This combination was chosen for its relative simplicity, likely good tolerance, low cost, high genetic barrier to resistance, and lack of interference with hepatitis B virus (HBV) replication (∼10% of the Thai population has HBV infection [14] ). Such a regimen, if proven effective, could be applied widely in a public health context.
METHODS

Study design. Program for HIV Prevention and Treatment (PHPT)-4 was a multicenter
, open-label trial to assess the incidence of NNRTI-resistance mutations in women who received a 1-month postpartum course of zidovudine plus didanosine in addition to antepartum zidovudine from 28 weeks plus single-dose nevirapine at onset of labor (ClinicalTrials.gov identifier: NCT00142337), compared with matched, historical controls from PHPT-2 [1] who received the same antepartum regimen (zidovudine and single-dose nevirapine) but no postpartum antiretroviral course (ClinicalTrials.gov identifier: NCT00398684). In both trials, infants received zidovudine and were not breast-fed.
A placebo-controlled study design was not considered for ethical reasons. Indeed, in 2004 when the trial was planned, we had already reported that exposure to single-dose nevirapine decreased the efficacy of subsequent nevirapine-containing HAART regimens [8] . Furthermore, preliminary results of a clinical trial in Africa showed that a 4-or 7-day postpartum course of zidovudine plus lamivudine could diminish, but not eliminate, the selection of nevirapine-resistance mutations [15] . The availability of stored samples collected during the PHPT-2 clinical trial conducted at the same sites provided satisfactory controls.
Subjects. Pregnant women participating in the Thai Ministry of Public Health's program for prevention of mother-tochild transmission of HIV at 37 hospitals in Thailand between January 2005 and September 2005 were offered enrollment in the PHPT-4 study. Inclusion criteria were age of 118 years, provision of written consent, and the following laboratory values within 21 days before enrollment: hemoglobin concentration, 18 .0 g/dL; absolute neutrophil count, 1750 cells/mm 3 ; alanine aminotransferase level !5 times the upper limit of normal; and creatinine level, !1.5 mg/dL. Exclusion criteria were a (1) CD4 cell count of !250 cells/mm 3 or medical need for HAART and (2) maternal or fetal condition or concomitant treatment contraindicating zidovudine or nevirapine.
PHPT-4 study subjects included in the analysis had received single-dose nevirapine and attended at least the 7-day postpartum visit. They were individually matched on the basis of HIV load, CD4 cell count at baseline, and duration of antepartum zidovudine to women enrolled between January 2001 and February 2003 in the PHPT-2 trial [1] and were observed for up to 120 days after delivery.
Study treatments and schedule of evaluations. PHPT-4 subjects and PHPT-2 controls received 300 mg zidovudine twice per day starting at 28 weeks' gestation or as soon as possible thereafter and 300 mg every 3 hours plus a 200-mg single dose of nevirapine during labor. Their infants received a 1-week postnatal course of zidovudine (2 mg/kg 4 times per day) plus a 6-mg single dose of nevirapine at 48-72 h of life. Premature infants received reduced zidovudine and, if they weighed !2500 g, nevirapine (2 mg/kg).
As opposed to PHPT-2 controls, PHPT-4 subjects received 1 dose of enteric-coated capsule of didanosine (400 mg) during labor. Zidovudine (300 mg twice per day) and didanosine (400 mg once per day, or 250 mg once per day if the weight was !60 kg) were continued for 1 month after delivery. Following a report of grade-4 postpartum anemia in July 2005, the postpartum zidovudine dose was reduced to 200 mg twice per day on the basis of results from a study [16] that showed that this dosage provided adequate zidovudine levels in Thai women who are generally small. None of the PHPT-2 control women received postpartum antiretroviral treatment.
Eligibility and entry criteria, antepartum evaluations in PHPT-4 and PHPT-2 were identical. After delivery, PHPT-2 women underwent a physical examination and virological evaluations at the 7-10-, 37-40-, and 120-day visits. PHPT-4 women had more extensive postpartum evaluations, with standard hematology and chemistry. Adherence was assessed at each visit by pill count. At the end of the study, women were referred to an internist for HIV care.
Laboratory procedures. Plasma HIV RNA levels were measured following the Cobas Amplicor HIV-1 Monitor RNA version 1.5 standard and, if below standard threshold, the ultrasensitive protocol (Roche Molecular Systems). Resistance mutations to NRTIs and NNRTIs were assayed on all available postpartum samples with a viral load 1500 copies/mL, and if mutations were detected, baseline samples were also assayed. Population sequencing was performed using the HIV-1 ViroSeq Genotyping System, version 2.6 (Celera Diagnostics, Alameda, USA) and interpretation based on the spring 2008 International AIDS Society USA Drug mutation tables (http://www.iasusa .org/resistance_mutations) [17] .
ViroSeq amplified products were tested using the Oligonucleotide Ligation Assay (OLA), a sensitive assay that can detect specific resistance mutations present in 15% of the viral population [18, 19] . The K103N, G190A, and Y181C NNRTI resistance mutations were tested using oligonucleotides designed for the CRF01_AE subtype prevalent in Thailand. Plasma samples with a viral load !500 copies/mL were considered negative for NNRTI mutations. Samples with nonamplifiable HIV polymerase gene or indeterminate OLA results were classified as missing.
Sample size and statistical analysis. We calculated that 219 evaluable subjects (244 enrolled subjects, taking into account that 10% would be nonevaluable) would provide adequate power (.05 one-sided type I error; power, 0.8) to detect a decreased incidence of resistance mutations from 20% in matched PHPT-2 controls to 10% in PHPT-4 women receiving postpartum zidovudine-didanosine treatment.
Baseline maternal and other study characteristics, including the incidence of NNRTI resistance mutations detected at all follow-up time points by both methods, were compared between groups using the Kruskal-Wallis, x 2 , and Fisher exact tests. A logistic regression analysis was used for PHPT-2 controls to test the association between postpartum NNRTI resistance mutations and baseline viral loads and CD4 cell count (categorized in terciles). Analyses were conducted using Stata Statistical Package (StataCorp). P values were 2-sided, without adjustment for multiple testing.
Ethics. The Thai Ministry of Public Health and Chiang Mai University Faculty of Medical Associated Sciences Ethics Committees approved the protocol including amendments.
RESULTS
Enrollment.
Of 302 HIV-positive eligible women, 257 were enrolled, 234 followed through delivery, 229 received singledose nevirapine, and 222 attended the 7-day postpartum visit. These 222 women were matched with PHPT-2 control women ( Figure 1 ).
Baseline characteristics and intervention. The baseline and delivery characteristics of the 222 PHPT-4 subjects and their PHPT-2 controls were similar, except for age. Table 1 provides baseline and delivery characteristics separately for the 2 groups. The combined groups' median CD4 cell count was 421 cells/mm 3 (interquartile range [IQR], 322-549 cells/mm 3 ), the HIV load was 3.45 log 10 copies/mL (IQR, 2.79-4.00 log 10 copies/mL), and duration of antepartum zidovudine treatment was 10.4 weeks (IQR, 9.1-11.4 weeks); median hemoglobin levels at enrollment and delivery were 11.1 g/dL (IQR, 10.4-11.9 g/dL) and 11.6 g/dL (IQR, 10.8-12.5 g/dL), respectively. PHPT-4 subjects and PHPT-2 controls received intrapartum nevirapine. Two PHPT-4 and 8 PHPT-2 women received 2 doses as a result of false or prolonged labor. In PHPT-4, seven women had received antepartum zidovudine and single-dose nevirapine in a previous pregnancy, and 1 woman had received antepartum zidovudine only. In PHPT-2, seven women had previously received antepartum zidovudine treatment.
In PHPT-4, a total of 117 women (53%) received the initial postpartum zidovudine dosing (300 mg twice per day) while others received 200 mg twice per day. One woman took no postpartum zidovudine-didanosine, and another took it for !2 weeks. One woman with prolonged labor initiated treatment with zidovudine plus didanosine after her first nevirapine dose; another who had false labor received zidovudine plus didanosine after her second nevirapine dose (5 days after the first). Twenty-two women (10%) missed 11 dose per week of either drug.
Postpartum HIV-1 RNA loads. The respective proportions of subjects with HIV RNA load !500 copies/mL at 7-10 days, 37-45 days, and 120 days after delivery were 85%, 54%, and 24% in PHPT-4, and 78%, 39%, and 45% in PHPT-2 ( Table  2 ). In PHPT-4 subjects, the median viral load was lowest at 7-10 days, and it returned to baseline levels 4 months after delivery.
HIV resistance to NNRTIs. No new major NNRTI resistance mutations-that is, mutations that alone confer high- level resistance to any NNRTI-were detected using consensus sequencing at anytime postpartum in PHPT-4 subjects. In contrast, у1 major NNRTI resistance mutation was detected in 23 PHPT-2 controls (10.4%). Ninety-one percent of sequenced viruses were of the CRF01_AE subtype. The incidence of mutations detected at each postpartum period is given in Table 3 and Figure 2 , and individual subjects' results shown in Table 4 . Using OLA, the K103N, G190A or Y181C mutations were detected postpartum in 4 PHPT-4 subjects (1.8%) versus 42 controls (18.9%). Among PHPT-4 women with resistance mutations, 1 had received single-dose nevirapine during a previous pregnancy. Two sequencing results were not confirmed by OLA on the same sample (Table 4 ). Baseline samples were tested in 93% of subjects with postpartum mutations and no mutations were detected. Combining the results of both assays, new postpartum resistance mutations were found in 1.8% of the PHPT-4 subjects versus 20.7% of PHPT-2 controls ( ), a 91% P ! .001 reduction in the selection of NNRTI resistance mutations.
In an analysis restricted to PHPT-2 control women, after adjusting for baseline CD4 cell count, only high baseline viral load was associated with postpartum NNRTI resistance mutations detected by either method ( ). P ! .001 Five PHPT-4 subjects and 8 PHPT-2 controls had minor NNRTI mutations in postpartum samples (V179D, K101E, V106I, or V90I). These mutations were also detected in 8 of the 10 baseline samples that could be amplified.
Resistance to NRTIs. One PHPT-4 subject and 2 PHPT-2 controls already had NRTI resistance mutations detected at baseline (T69N in 2 and M41L in 1). After a median antepartum zidovudine duration of 10.4 weeks in both groups and an additional 4 weeks postpartum zidovudine plus didanosine in PHPT-4, new NRTI resistance mutations were detected by consensus sequencing in 5 PHPT-4 subjects (2.3%; K70R in 4 and D67N plus K70R in 1) and 2 PHPT-2 controls (0.9%; D67N and K70R in 1 each) ( Table 4) . Maternal safety. The proportion of subjects who experienced a serious adverse event between delivery and 4 months after delivery was similar in PHPT-4 subjects and controls (4.5% and 3.1%, respectively). In PHPT-4 women, 1 postpartum hemorrhage with grade-4 anemia (hemoglobin concentration, 6.3 g/dL), 1 stillbirth, 4 infections, 1 grade-4 lipase elevation (10 times the upper limit of normal), 1 grade-4 anemia (hemoglobin concentration, 6.5 g/dL), and 1 gastritis were reported. In PHPT-2 women, 3 postpartum hemorrhages, 3 infections, and 1 grade-4 elevation in the alanine aminotransferase level (21 times the upper limit of normal) were reported. Ten days after delivery, mild rash was reported in 2.7% of PHPT-4 subjects and 2.3% of controls. Also, grade-1 or grade-2 elevated alanine aminotransferase were reported in 4.4% of PHPT-4 women and 3.6% of controls.
In PHPT-4 subjects, the median hemoglobin concentration was 11.7 g/dL (IQR, 10.9-12.5 g/dL) at 1 month after delivery (11.6 g/dL [IQR, 10.9-12.5 g/dL] for the initial 300-mg twicedaily zidovudine dosing and 11.9 g/dL [IQR, 10.9-12.5 g/dL] at 200 mg;
). Two PHPT-4 women experienced grade-P p .20 4 anemia and 2 grade-3 anemia. Anemia was not reported in control women, but because hemoglobin levels were not prospectively measured, subclinical anemia may have occurred.
Mother-to-child HIV transmission. Although HIV transmission was not an outcome of this study, it was measured. Among 176 PHPT-4 infants with DNA PCR data, 4 were infected (2.3%; 95% confidence interval, 0.6%-6.0%), and none were infected in the PHPT-2 group (95% confidence interval, 0%-1.6%). None of the women previously exposed to antepartum zidovudine and single dose nevirapine transmitted HIV to her infants. !.001 a Mutations associated with low level of resistance to the second-generation nonnucleoside reverse-transcriptase inhibitor resistance etravirine, such as V90I, K101E, V106I, and V179D-most of which were present at baseline-were not considered.
DISCUSSION
Following single-dose nevirapine during labor, 1 month of zidovudine plus didanosine after delivery in women with no indication for therapy for their own health, virtually eliminated the selection of HIV NNRTI resistance mutations. Only low concentrations of virus quasi-species with resistance mutations, expected to decay rapidly could be detected by OLA; they were no longer detectable at 4 months. During the 4-month postpartum follow-up, combining the results of both assays, major resistance mutations to NNRTIs were detected in 1.8% of the mothers who received postpartum zidovudine-didanosine versus 20.7% of the control women ( ), a 91% reduction P ! .001 in the selection of NNRTI resistance mutations. The 1-month postpartum regimen appeared to be safe, well tolerated, and easy to adhere to.
PHPT-4 subjects and controls matched on CD4 cell count, antepartum zidovudine duration and plasma viral load did not differ for any baseline characteristics other than age. Surprisingly the 4-month postpartum viral loads were lower in PHPT-2 controls than in PHPT-4 subjects and lower than at baseline. Indeed, in PHPT-2 controls, postpartum viral loads were measured on samples stored frozen for several years, whereas baseline samples were tested on a real time basis. Therefore, the prevalence of NNRTI resistance mutations in the control group may have been underestimated, and the difference between the 2 groups may be greater than that reported here. The fact that in PHPT-4, 85% of women had undetectable viral load at 7-10 days and 54% at 37-45 days after delivery, reflects the antiretroviral activity of zidovudine plus didanosine combined with nevirapine, which remains at clinically significant levels for up to 20 days after single-dose administration [13] .
A meta-analysis estimated the incidence of postexposure nevirapine resistance mutations detected by consensus sequencing at 35.7%, with a lower incidence in women who received antepartum antiretrovirals [20] . As expected, the incidence of resistance mutations in PHPT-2 controls was lower, because women with CD4 cell count !250 cells/mm 3 and likely higher viral loads were not eligible. Differences across studies may also be partly explained by the virus subtypes prevalent in each population. In Africa, subtype C viruses-and, to a lesser extent, subtype D-have more often than subtype A been associated with the selection of resistance mutations after singledose nevirapine [21, 22] . Although no direct comparison can be made with subtypes prevalent in Thailand, the incidence of resistance with subtype C appears to be higher than with subtypes E/B. For example, in Zambia where subtype C predominates, the prevalence of NNRTI resistance mutations at 6 weeks after delivery in a similar population (women not eligible for HAART who received antepartum zidovudine) was 25% using population sequencing (44% with OLA) [23] , compared with 6.4% (13.2% with OLA) in PHPT-2 participants.
In an attempt to limit the selection of nevirapine resistance mutations, several postexposure antiretroviral regimens have been evaluated. In a South African randomized trial [15] the incidence of resistance mutations detectable by population sequencing at 2 and 6 weeks after delivery was reduced from 57% to 13% or 9% with a 4-or 7-day postpartum course of zidovudine plus lamivudine, respectively. In Cote d'Ivoire, zidovudine-lamivudine treatment given from 32 weeks gestation to 3 days after delivery reduced the incidence of resistance mutations detected at 4 weeks from 33% in historical controls to 1% [24] . However, lamivudine resistance mutations, associated with subsequent failure of lamivudine-containing regimens, were reported in 8% of women [25] . In Zambia, women not eligible for HAART who received short-course zidovudine plus intrapartum nevirapine, received either single-dose tenofovir-emtricitabine during labor or no intervention [26] . At 6 weeks after delivery, tenofovir-emtricitabine reduced NNRTI resistance mutations detected by population sequencing from 25% to 12%, and by OLA from 45% to 20% [23] . Finally, in the TEmAA ANRS12109 study [27] , no resistance mutations were detected by population sequencing at 4 weeks delivery in 37 women with CD4 cell counts 1200 cells/mm 3 who received antepartum zidovudine, intrapartum single-dose nevirapine together with double-dose tenofovir-emtricitabine, continued for 1 week once daily. The duration of antiretroviral regimen in this study was longer than regimens evaluated elsewhere but appeared much more efficacious in preventing resistance mutations.
Genotypes perceived to have "minor" contributions to resistance to second generation of NNRTI, etravirine, were detected in several consecutive postpartum samples as well as before nevirapine exposure. These mutations are known polymorphisms in subtype CRF01_AE.
The 1-month zidovudine-didanosine regimen evaluated in this study appeared to be safe. It bears minimal risk of selecting NRTI resistance mutations and can be offered to women with HBV coinfection as these drugs do not interfere with HBV replication. HBV infection affects ∼10% of the southeast Asia population, and HBV flare with a risk of clinical acute hepatitis have been reported following discontinuation of treatments containing lamivudine, emtricitabine or tenofovir [28] [29] [30] .
This one month regimen of zidovudine-didanosine maintained viral replication at low levels for the duration which nevirapine may be present at significant levels (Table 2) [13] . This confirms that inhibiting viral replication during nevirapine exposure is an effective approach to prevent the selection of resistance mutations. Preliminary results from another study indicate that a more potent postpartum regimen (boosted lopinavir, zidovudine, and didanosine) for a shorter period of time may have a similar efficacy [31] .
The HIV transmission rate in PHPT-4 subjects was 2.2%, compared with 0% among PHPT-2 controls. The absence of perinatal transmissions in the PHPT-2 control group may have been due to chance, because the overall transmission rate of transmission in the PHPT-2 group of women with a CD4 cell count 1250 cells/mm 3 from which control women was randomly selected, was 1.4% (95% confidence interval, 0.6%-2.9%; data not shown).
HAART is increasingly used during pregnancy for the prevention of mother-to-child transmission of HIV regardless of the woman's immune status. However, for the many women who are diagnosed late in pregnancy or at delivery, intrapartum nevirapine will continue to be an essential component of the prevention of perinatal HIV. Therefore, interventions to eliminate post-exposure selection of nevirapine resistance are critical to safeguard a highly efficacious intervention for the prevention of mother-to-child transmission while preserving the mother's future therapeutic options.
